1. Home
  2. RSSS vs FLNA Comparison

RSSS vs FLNA Comparison

Compare RSSS & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Research Solutions Inc

RSSS

Research Solutions Inc

HOLD

Current Price

$2.22

Market Cap

73.6M

ML Signal

HOLD

FLNA

Filana Therapeutics Inc. Common Stock

N/A

Current Price

$0.96

Market Cap

61.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RSSS
FLNA
Founded
2006
1998
Country
United States
United States
Employees
N/A
20
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.6M
61.8M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
RSSS
FLNA
Price
$2.22
$0.96
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
29.7K
356.9K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
130.77
N/A
EPS
0.07
N/A
Revenue
$28,793,922.00
N/A
Revenue This Year
$1.81
N/A
Revenue Next Year
$5.73
N/A
P/E Ratio
$32.00
N/A
Revenue Growth
2.77
N/A
52 Week Low
$2.00
$0.86
52 Week High
$4.12
$2.03

Technical Indicators

Market Signals
Indicator
RSSS
FLNA
Relative Strength Index (RSI) 48.65 22.93
Support Level $2.16 N/A
Resistance Level $2.37 $1.80
Average True Range (ATR) 0.06 0.05
MACD -0.00 -0.02
Stochastic Oscillator 55.37 3.73

Price Performance

Historical Comparison
RSSS
FLNA

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.

About FLNA Filana Therapeutics Inc. Common Stock

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Share on Social Networks: